The Latin America, Middle East and Africa Uveitis Treatment Market is expected to witness market growth of 6.5% CAGR during the forecast period (2019-2025).
For the treatment of infectious uveitis, certain medications have advantages over others. Topical and systemic treatments are often used in the treatment of ocular infection, but the treatment route may be limited by penetration, concentration, and duration. The advent of antimicrobial intravitreal therapy has furthered the treatment of intraocular infections. With limited systemic absorption, being able to overcome blood-ocular barriers allows for large concentrations of drugs to be administered directly to the posterior section. Nevertheless, because the difference between the therapeutic and toxic doses of certain antimicrobial drugs falls within a small range of concentration, intravitreal therapy can be associated with risks of ocular toxicity.
Intermediate uveitis is a vitreous and peripheral retina-localized type of uveitis. Primary inflammatory sites include the vitreous which includes other entities such as pars planitis, posterior cyclitis, and hyalitis. Intermediate uveitis may be either an isolated eye disease or related to the development of a systemic condition such as multiple sclerosis or sarcoidosis. As such, the first manifestation of a systemic disorder may be intermediate uveitis. Infectious causes of intermediate uveitis include infection with the Epstein-Barr virus, Lyme disease, HTLV-1 virus, cat scratch disease, and hepatitis C.
Permanent vision loss is most often observed in patients suffering from chronic cystoid macular edema (CME). While present, every attempt must be made to eliminate CME. Retinal detachment, glaucoma, band keratopathy, cataract, vitreous hemorrhage, epiretinal membrane, and choroidal neovascularization are also less common causes of visual impairment.
Based on Drug Class, the market is segmented into Anti-inflammatory, Immunotherapy & Targeted Therapies, Antimicrobial Drugs and Other Drug Class. Based on Disease Type, the market is segmented into Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis and Panuveitis. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online stores. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Alimera Sciences, Inc., Enzo Biochem, Inc., Amgen, Inc., Bausch Health Companies, Inc., Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., TopiVert Ltd., and Novartis AG.
Scope of the Study
Market Segmentation:
By Drug Class
By Disease Type
By Distribution Channel
By Country
Companies Profiled
Unique Offerings from the Publisher
For the treatment of infectious uveitis, certain medications have advantages over others. Topical and systemic treatments are often used in the treatment of ocular infection, but the treatment route may be limited by penetration, concentration, and duration. The advent of antimicrobial intravitreal therapy has furthered the treatment of intraocular infections. With limited systemic absorption, being able to overcome blood-ocular barriers allows for large concentrations of drugs to be administered directly to the posterior section. Nevertheless, because the difference between the therapeutic and toxic doses of certain antimicrobial drugs falls within a small range of concentration, intravitreal therapy can be associated with risks of ocular toxicity.
Intermediate uveitis is a vitreous and peripheral retina-localized type of uveitis. Primary inflammatory sites include the vitreous which includes other entities such as pars planitis, posterior cyclitis, and hyalitis. Intermediate uveitis may be either an isolated eye disease or related to the development of a systemic condition such as multiple sclerosis or sarcoidosis. As such, the first manifestation of a systemic disorder may be intermediate uveitis. Infectious causes of intermediate uveitis include infection with the Epstein-Barr virus, Lyme disease, HTLV-1 virus, cat scratch disease, and hepatitis C.
Permanent vision loss is most often observed in patients suffering from chronic cystoid macular edema (CME). While present, every attempt must be made to eliminate CME. Retinal detachment, glaucoma, band keratopathy, cataract, vitreous hemorrhage, epiretinal membrane, and choroidal neovascularization are also less common causes of visual impairment.
Based on Drug Class, the market is segmented into Anti-inflammatory, Immunotherapy & Targeted Therapies, Antimicrobial Drugs and Other Drug Class. Based on Disease Type, the market is segmented into Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis and Panuveitis. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online stores. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Alimera Sciences, Inc., Enzo Biochem, Inc., Amgen, Inc., Bausch Health Companies, Inc., Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., TopiVert Ltd., and Novartis AG.
Scope of the Study
Market Segmentation:
By Drug Class
- Anti-inflammatory
- Immunotherapy & Targeted Therapies
- Antimicrobial Drugs
- Other Drug Class
By Disease Type
- Anterior Uveitis
- Posterior Uveitis
- Intermediate Uveitis
- Panuveitis
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online stores
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Companies Profiled
- AbbVie, Inc.
- Alimera Sciences, Inc.
- Enzo Biochem, Inc.
- Amgen, Inc.
- Bausch Health Companies, Inc.
- Clearside Biomedical, Inc.
- EyePoint Pharmaceuticals, Inc.
- Santen Pharmaceutical Co., Ltd.
- TopiVert Ltd.
- Novartis AG
Unique Offerings from the Publisher
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. LAMEA Uveitis Treatment Market by Drug Class
Chapter 4. LAMEA Uveitis Treatment Market by Disease Type
Chapter 5. LAMEA Uveitis Treatment Market by Distribution Channel
Chapter 6. LAMEA Uveitis Treatment Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- AbbVie, Inc.
- Alimera Sciences, Inc.
- Enzo Biochem, Inc.
- Amgen, Inc.
- Bausch Health Companies, Inc.
- Clearside Biomedical, Inc.
- EyePoint Pharmaceuticals, Inc.
- Santen Pharmaceutical Co., Ltd.
- TopiVert Ltd.
- Novartis AG
Methodology
LOADING...
